HB1801
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.HB1801 is one of 89 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
3
Indications
9
Total Trials
8
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1HB1801
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2027
Phase 2Not yet recruiting
Breast Cancer
NCT07116824
Phase 1/2Not yet recruiting
Locally Advanced or Metastatic Solid Tumors
NCT06682611
Phase 2/3Not yet recruiting
Non-Small Cell Lung Cancer
NCT06319313
Phase 3Active, not recruiting
HER2-Positive Breast Cancer
NCT06747338
Phase 3Recruiting
Breast Cancer
NCT05838066
Clinical
Trials by Indication[1]
Breast Cancer5 trials
Non-Small Cell Lung Cancer2 trials
Locally Advanced or Metastatic Solid Tumors1 trial
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Not yet recruiting·SShanghai Runshi Pharmaceutical Technology Co., Ltd·Phase 1/2·NCT06682611·380 enrolled
HER2-positive Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB1801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details